[1]
|
中华医学会糖尿病学分会代谢综合征研究协作组. 中华医学会糖尿病学分会关于代谢综合征的建议[J]. 中华糖尿病杂志, 2004, 12(3): 156-161.
|
[2]
|
李燕萍, 周裕婧, 朱士胜, 赵晓龙. 中国老年人代谢综合征患病率META分析[J]. 现代预防医学, 2022, 49(5): 913-917.
|
[3]
|
Ineichen, G.B. and Burkhard, F.C. (2021) Metabolic Syndrome and Male Lower Urinary Tract Symptoms. Panminerva Medica, 64, 329-336.
|
[4]
|
Medina, J.S. and Rodríguez, J.C. (2016) A Review of the Pathophysiological Factors Involved in Urological Disease Associated with Metabolic Syndrome. Actas Urológicas Españolas (English Edition), 40, 279-287.
https://doi.org/10.1016/j.acuroe.2016.03.010
|
[5]
|
Bitzur, R., Brenner, R., Maor, E., Antebi, M., Ziv-Baran, T., Segev, S., Sidi, Y. and Kivity, S. (2016) Metabolic Syndrome, Obesity, and the Risk of Cancer Development. European Journal of Internal Medicine, 34, 89-93.
https://doi.org/10.1016/j.ejim.2016.08.019
|
[6]
|
Laukkanen, J.A., et al. (2004) Metabolic Syndrome and the Risk of Prostate Cancer in Finnish Men: A Population-Based Study. Cancer Epidemiology, Biomarkers & Prevention, 13, 1646-1650.
https://doi.org/10.1158/1055-9965.1646.13.10
|
[7]
|
Hammarsten, J. and Peeker, R. (2011) Urological Aspects of the Metabolic Syndrome. Nature Reviews Urology, 8, 483-494. https://doi.org/10.1038/nrurol.2011.112
|
[8]
|
Zhang, G.-M., Zhu, Y., Dong, D.-H., Han, C.-T., Gu, C.-Y., Gu, W.-J., et al. (2015) The Association between Metabolic Syn-drome and Advanced Prostate Cancer in Chinese Patients Receiving Radical Prostatectomy. Asian Journal of Andrology, 17, 839-844. https://doi.org/10.4103/1008-682X.148138
|
[9]
|
Bhindi, B., et al. (2016) Influence of Metabolic Syn-drome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy. Urol-ogy, 93, 77-85. https://doi.org/10.1016/j.urology.2016.01.041
|
[10]
|
Gacci, M., Russo, G.I., De Nunzio, C., Sebas-tianelli, A., Salvi, M., Vignozzi, L., et al. (2017) Meta-Analysis of Metabolic Syndrome and Prostate Cancer. Prostate Cancer and Prostatic Diseases, 20, 146-155.
https://doi.org/10.1038/pcan.2017.1
|
[11]
|
Damiano, R., Cicione, A. and Cantiello, F. (2015) Re: Dissecting the As-sociation between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort. European Urolo-gy, 67, 972-973.
https://doi.org/10.1016/j.eururo.2014.12.062
|
[12]
|
Bhindi, B., Locke, J., et al. (2015) Dissecting the Association between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort. European Urology, 67, 64-70. https://doi.org/10.1016/j.eururo.2014.01.040
|
[13]
|
Monroy-Iglesias, M.J., Russell, B., Crawley, D., Allen, N.E., Travis, R.C., et al. (2021) Metabolic Syndrome Biomarkers and Prostate Cancer Risk in the UK Biobank. Interna-tional Journal of Cancer, 148, 825-834.
https://doi.org/10.1002/ijc.33255
|
[14]
|
Olivas, A. and Price, R.S. (2020) Obesity, Inflammation, and Advanced Prostate Cancer. Nutrition and Cancer, 73, 2232-2248. https://doi.org/10.1080/01635581.2020.1856889
|
[15]
|
Golabek, T., Bukowczan, J., Chłosta, P., et al. (2014) Obe-sity and Prostate Cancer Incidence and Mortality: A Systematic Review of Prospective Cohort Studies. Urologia Interna-tionalis, 92, 7-14. https://doi.org/10.1159/000351325
|
[16]
|
Allott, E.H., Masko, E.M. and Freedland, S.J. (2013) Obesity and Prostate Cancer: Weighing the Evidence. European Urology, 63, 800-809. https://doi.org/10.1016/j.eururo.2012.11.013
|
[17]
|
Rivera-Izquierdo, M., de Rojas, J.P., et al. (2022) Obesity and Biochemical Recurrence in Clinically Localised Prostate Cancer: A Systematic Review and Meta-Analysis of 86,490 Pa-tients. Prostate Cancer and Prostatic Diseases, 25, 411-421. https://doi.org/10.1038/s41391-021-00481-7
|
[18]
|
Stevens, V.L., Jacobs, E.J., Maliniak, M.L., Patel, A.V. and Gapstur, S.M. (2017) No Association of Waist Circumference and Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiology, Biomarkers & Prevention, 26, 1812-1814. https://doi.org/10.1158/1055-9965.EPI-17-0802
|
[19]
|
Demarzo, A.M., Nelson, W.G., Isaacs, W.B. and Epstein, J.I. (2003) Pathological and Molecular Aspects of Prostate Cancer. The Lancet, 361, 955-964. https://doi.org/10.1016/S0140-6736(03)12779-1
|
[20]
|
Tumminia, A., Vinciguerra, F., Parisi, M., Graziano, M., Sciacca, L., Baratta, R. and Frittitta, L. (2019) Adipose Tissue, Obesity and Adiponectin: Role in Endocrine Cancer Risk. International Journal of Molecular Sciences, 20, Article No. 2863. https://doi.org/10.3390/ijms20122863
|
[21]
|
Mistry, T., Digby, J.E., Desai, K.M. and Randeva, H.S. (2007) Obesity and Prostate Cancer: A Role for Adipokines. European Urology, 52, 46-53. https://doi.org/10.1016/j.eururo.2007.03.054
|
[22]
|
Nguyen, D.P., Li, J. and Tewari, A.K. (2014) Inflammation and Prostate Cancer: The Role of Interleukin 6 (IL-6). BJU International, 113, 986-992. https://doi.org/10.1111/bju.12452
|
[23]
|
Natani, S., Sruthi, K.K., Asha, S.M., Khilar, P., et al. (2022) Activation of TGF-β—SMAD2 Signaling by IL-6 Drives Neuroendocrine Differentiation of Prostate Cancer through p38MAPK. Cellular Signalling, 91, Article ID: 110240.
https://doi.org/10.1016/j.cellsig.2021.110240
|
[24]
|
Bandini M., Gandaglia, G. and Briganti, A. (2017) Obesity and Prostate Cancer. Current Opinion in Urology, 27, 415-421. https://doi.org/10.1097/MOU.0000000000000424
|
[25]
|
Noto, H., Tsujimoto, T. and Noda, M. (2012) Significantly Increased Risk of Cancer in Diabetes Mellitus Patients: A Meta-Analysis of Epidemiological Evidence in Asians and Non-Asians. Journal of Diabetes Investigation, 3, 24-33.
https://doi.org/10.1111/j.2040-1124.2011.00183.x
|
[26]
|
Handelsman, Y., Leroith, D., Bloomgarden, Z.T., Da-gogo-Jack, S., Einhorn, D., Garber, A.J., et al. (2013) Diabetes and Cancer—An AACE/ACE Consensus Statement. Endocrine Practice, 19, 675-693.
https://doi.org/10.4158/EP13248.CS
|
[27]
|
Chen, Y., Wu, F., Saito, E., Lin, Y.S., Song, M., et al. (2017) Associa-tion between Type 2 Diabetes and Risk of Cancer Mortality: A Pooled Analysis of over 771,000 Individuals in the Asia Cohort Consortium. Diabetologia, 60, 1022-1032.
https://doi.org/10.1007/s00125-017-4229-z
|
[28]
|
Long, X.-J., Lin, S., Sun, Y.-N. and Zheng, Z.-F. (2012) Diabetes Mellitus and Prostate Cancer Risk in Asian Countries: A Meta-Analysis. Asian Pacific Journal of Cancer Prevention: APJCP, 13, 4097-4100.
https://doi.org/10.7314/APJCP.2012.13.8.4097
|
[29]
|
Tseng, C. (2022) Pioglitazone and Prostate Cancer Risk in Taiwanese Male Patients with Type 2 Diabetes: A Retrospective Cohort Study. The World Journal of Men’s Health, 41, 119-128. https://doi.org/10.5534/wjmh.210157
|
[30]
|
Li, X.J., Li, J., Cai, Y., Peng, S.B., Wang, J., Xiao, Z.M., Wang, Y., Tao, Y.R., Li, J., Leng, Q., Wu, D.L., Yang, S.D., Ji, Z.L., Han, Y.F., Li, L.R., Gao, X., Zeng, C.X. and Wen, X.Q. (2018) Hyperglycaemia-Induced miR-301a Promotes Cell Proliferation by Repressing p21 and Smad4 in Prostate Cancer. Cancer Letters, 418, 211-220.
https://doi.org/10.1016/j.canlet.2018.01.031
|
[31]
|
Hankinson, S.J., Fam, M. and Patel, N.N. (2017) A Review for Clinicians: Prostate Cancer and the Antineoplastic Properties of Metformin. Urologic Oncology: Seminars and Original Investigations, 35, 21-29.
https://doi.org/10.1016/j.urolonc.2016.10.009
|
[32]
|
Vancura, A., Bu, P.L., Bhagwat, M., Zeng, J. and Vancurova, I. (2018) Metformin as an Anticancer Agent. Trends in Pharmacological Sciences, 39, 867-878. https://doi.org/10.1016/j.tips.2018.07.006
|
[33]
|
Tseng, C.-H. (2014) Metformin Significantly Reduces Incident Prostate Cancer Risk in Taiwanese Men with Type 2 Diabetes Mellitus. European Journal of Cancer, 50, 2831-2837. https://doi.org/10.1016/j.ejca.2014.08.007
|
[34]
|
Wang, Y., Liu, G.L., Tong, D.L., Parmar, H., Hasenmayer, D., Yuan, W.Q., Zhang, D.Z. and Jiang, J. (2015) Metformin Represses Androgen-Dependent and Androgen-Independent Prostate Cancers by Targeting Androgen Receptor. The Prostate, 75, 1187-1196. https://doi.org/10.1002/pros.23000
|
[35]
|
Grossmann, M. and Wittert, G. (2012) Androgens, Diabetes and Prostate Cancer. Endocrine-Related Cancer, 19, F47-F62. https://doi.org/10.1530/ERC-12-0067
|
[36]
|
Kuo, Y.-J., Sung, F.-C., Hsieh, P.-F., Chang, H.-P., Wu, K.-L. and Wu, H.-C. (2019) Metformin Reduces Prostate Cancer Risk among Men with Benign Prostatic Hyperplasia: A Nationwide Population-Based Cohort Study. Cancer Medicine, 8, 2514-2523. https://doi.org/10.1002/cam4.2025
|
[37]
|
Škara, L., et al. (2021) Prostate Cancer—Focus on Cholesterol. Cancers, 13, Article No. 4696.
https://doi.org/10.3390/cancers13184696
|
[38]
|
Renehan, A.G., Zwahlen, M., Minder, C., et al. (2004) Insulin-Like Growth Factor (IGF)-I, IGF Binding Protein-3, and Cancer Risk: Systematic Review and Meta-Regression Analysis. The Lancet (London, England), 363, 1346-1353.
https://doi.org/10.1016/S0140-6736(04)16044-3
|
[39]
|
Arthur, R., Møller, H., Garmo, H., Holmberg, L., Stattin, P., Malmstrom, H., et al. (2016) Association between Baseline Serum Glucose, Triglycerides and Total Cholesterol, and Prostate Cancer Risk Categories. Cancer Medicine, 5, 1307-1318. https://doi.org/10.1002/cam4.665
|
[40]
|
Katzke, V.A., Sookthai, D., Johnson, T., Kühn, T. and Kaaks, R. (2017) Blood Lipids and Lipoproteins in Relation to Incidence and Mortality Risks for CVD and Cancer in the Prospective EPIC—Heidelberg Cohort. BMC Medicine, 15, Article No. 218. https://doi.org/10.1186/s12916-017-0976-4
|
[41]
|
陈杰翔, 安宏元, 李利. 前列腺癌患者血脂水平及临床意义[J]. 中国老年学杂志, 2021, 41(18): 3950-3952.
|
[42]
|
Revilla, G., et al. (2020) LDL, HDL and Endocrine-Related Cancer: From Pathogenic Mechanisms to Therapies. Seminars in Cancer Biology, 73, 134-157. https://doi.org/10.1016/j.semcancer.2020.11.012
|
[43]
|
Van Hemelrijck, M., Walldius, G., Jungner, I., Hammar, N., Garmo, H., et al. (2011) Low Levels of Apolipoprotein A-I and HDL Are Associated with Risk of Prostate Cancer in the Swedish AMORIS Study. Cancer Causes & Control, 22, 1011-1019. https://doi.org/10.1007/s10552-011-9774-z
|
[44]
|
Liu, Y.P., Zhang, Y.X., Li, P.F., Cheng, C., Zhao, Y.S., Li, D.P. and Du, C. (2015) Cholesterol Levels in Blood and the Risk of Prostate Cancer: A Meta-Analysis of 14 Prospective Studies. Cancer Epidemiology, Biomarkers & Prevention, 24, 1086-1093. https://doi.org/10.1158/1055-9965.EPI-14-1329
|
[45]
|
O’neill, S. and O’driscoll, L. (2015) Metabolic Syndrome: A Closer Look at the Growing Epidemic and Its Associated Pathologies. Obesity Reviews: An Official Journal of the Inter-national Association for the Study of Obesity, 16, 1-12.
https://doi.org/10.1111/obr.12229
|
[46]
|
金头峰, 全贞玉. 结直肠癌患者血脂、白细胞和维生素E水平分析[J]. 中国慢性病预防与控制, 2010, 18(4): 399-400.
|
[47]
|
Wang, H., Yan, W., Sun, Y.H., et al. (2022) High-Fat Di-et-Induced Hyperinsulinemia Promotes the Development of Prostate Adenocarcinoma in Prostate Specific Pten-/- Mice. Carcinogenesis, 43, 504-516.
https://doi.org/10.1093/carcin/bgac013
|
[48]
|
Chamie, K., Oberfoell, S., Kwan, L., et al. (2013) Body Mass Index and Prostate Cancer Severity: Do Obese Men Harbor More Aggressive Disease on Prostate Biopsy? Urology, 81, 949-955.
https://doi.org/10.1016/j.urology.2013.01.021
|
[49]
|
Zamanian-Daryoush, M. and Didonato, J.A. (2015) Apolipo-protein A-I and Cancer. Frontiers in Pharmacology, 6, Article No. 265. https://doi.org/10.3389/fphar.2015.00265
|
[50]
|
Su, F., Grijalva, V., Navab, K., et al. (2012) HDL Mimetics Inhibit Tumor Development in both Induced and Spontaneous Mouse Models of Colon Cancer. Molecular Cancer Therapeutics, 11, 1311-1319.
https://doi.org/10.1158/1535-7163.MCT-11-0905
|
[51]
|
Soran, H., Hama, S., Yadav, R. and Durrington, P.N. (2012) HDL Functionality. Current Opinion in Lipidology, 23, 353-366. https://doi.org/10.1097/MOL.0b013e328355ca25
|
[52]
|
Eckardstein A., Hersberger, M. and Rohrer, L. (2005) Cur-rent Understanding of the Metabolism and Biological Actions of HDL. Current Opinion in Clinical Nutrition and Meta-bolic Care, 8, 147-152.
https://doi.org/10.1097/00075197-200503000-00007
|
[53]
|
Zhao, R.Z., Cheng, G., Wang, B., Qin, C., Liu, Y., Pan, Y.S., et al. (2017) BMI and Serum Lipid Parameters Predict Increasing Risk and Aggressive Prostate Cancer in Chinese People. Oncotarget, 8, 66051-66060.
https://doi.org/10.18632/oncotarget.19790
|
[54]
|
Iso, H., Ikeda, A., Inoue, M., Sato, S. and Tsugane, S. (2009) Se-rum Cholesterol Levels in Relation to the Incidence of Cancer: The JPHC Study Cohorts. International Journal of Can-cer, 125, 2679-2686. https://doi.org/10.1002/ijc.24668
|
[55]
|
Wu, Q., Ishikawa, T., Sirianni, R., Tang, H., et al. (2013) 27-Hydroxycholesterol Promotes Cell-Autonomous, ER-Positive Breast Cancer Growth. Cell Reports, 5, 637-645. https://doi.org/10.1016/j.celrep.2013.10.006
|
[56]
|
Pelton, K., et al. (2012) Cholesterol and Prostate Cancer. Current Opinion in Pharmacology, 12, 751-759.
https://doi.org/10.1016/j.coph.2012.07.006
|
[57]
|
Saxena, N., Beraldi, E., Fazli, L., et al. (2021) Androgen Receptor (AR) Antagonism Triggers Acute Succinate-Mediated Adaptive Responses to Reactivate AR Signaling. EMBO Molecu-lar Medicine, 13, e13427.
https://doi.org/10.15252/emmm.202013427
|
[58]
|
Pai, P.-Y., Hsieh, V.C.-R., Wang, C.-B., et al. (2015) Long Term Antihypertensive Drug Use and Prostate Cancer Risk: A 9-Year Population-Based Cohort Analysis. International Jour-nal of Cardiology, 193, 1-7.
https://doi.org/10.1016/j.ijcard.2015.05.042
|
[59]
|
Beebe-Dimmer, J.L., Dunn, R.L., Sarma, A.V., Montie, J.E. and Cooney, K.A. (2007) Features of the Metabolic Syndrome and Prostate Cancer in African-American Men. Cancer, 109, 875-881. https://doi.org/10.1002/cncr.22461
|
[60]
|
Stikbakke, E., Schirmer, H., Knutsen, T., Støyten, M., Wilsgaard, T., et al. (2021) Systolic and Diastolic Blood Pressure, Prostate Cancer Risk, Treatment, and Survival. The PROCA-Life Study. Cancer Medicine, 11, 1005-1015.
https://doi.org/10.1002/cam4.4523
|
[61]
|
Liang, Z., Xie, B., Li, J.F., Wang, X., Wang, S., Meng, S., et al. (2016) Hypertension and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis. Scientific Reports, 6, Article No. 31358. https://doi.org/10.1038/srep31358
|
[62]
|
Tuohimaa, P., Tenkanen, L., Syvälä, H., Lumme, S., Hakulinen, T., Dillner, J. and Hakama, M. (2007) Interaction of Factors Related to the Metabolic Syndrome and Vitamin D on Risk of Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention, 16, 302-307. https://doi.org/10.1158/1055-9965.EPI-06-0777
|
[63]
|
Christakoudi, S., Kakourou, A., Markozannes, G., Tzoulaki, I., Weiderpass, E., Brennan, P., et al. (2020) Blood Pressure and Risk of Cancer in the European Prospective Investiga-tion into Cancer and Nutrition. International Journal of Cancer, 146, 2680-2693. https://doi.org/10.1002/ijc.32576
|
[64]
|
Stocks, T., Hergens, M.-P., Englund, A., Ye, W.M. and Stattin, P. (2010) Blood Pressure, Body Size and Prostate Cancer Risk in the Swedish Construction Workers Cohort. International Journal of Cancer, 127, 1660-1668.
https://doi.org/10.1002/ijc.25171
|
[65]
|
Wallner, L.P., Morgenstern, H., Mcgree, M.E., et al. (2011) The Effects of Metabolic Conditions on Prostate Cancer Incidence over 15 Years of Follow-Up: Results from the Olmsted County Study. BJU International, 107, 929-935.
https://doi.org/10.1111/j.1464-410X.2010.09703.x
|
[66]
|
Hadrava, V., Tremblay, J. and Hamet, P. (1989) Abnor-malities in Growth Characteristics of Aortic Smooth Muscle Cells in Spontaneously Hypertensive Rats. Hypertension (Dallas, Tex.: 1979), 13, 589-597.
https://doi.org/10.1161/01.HYP.13.6.589
|
[67]
|
Martin, R.M., Vatten, L., Gunnell, D. and Romundstad, P. (2010) Blood Pressure and Risk of Prostate Cancer: Cohort Norway (CONOR). Cancer Causes & Control: CCC, 21, 463-472. https://doi.org/10.1007/s10552-009-9477-x
|
[68]
|
Uemura, H., Hoshino, K. and Kubota, Y. (2011) Engagement of Renin-Angiotensin System in Prostate Cancer. Current Cancer Drug Targets, 11, 442-450. https://doi.org/10.2174/156800911795538101
|
[69]
|
De Nunzio, C., Aronson, W., Freedland, S.J., Giovannucci, E. and Parsons, J.K. (2012) The Correlation between Metabolic Syndrome and Prostatic Diseases. European Urology, 61, 560-570.
https://doi.org/10.1016/j.eururo.2011.11.013
|